NEWNAN, Ga., Sept. 16 /PRNewswire/ -- CeloNova BioSciences, Inc. today announced that Franco Orsi, MD, PhD, will make two presentations at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) conference about "micro-bland embolization" which has demonstrated excellent clinical results in treating liver cancer. Professor Orsi and his colleagues at the European Institute of Oncology in Milan, Italy have developed a technique to cut off the blood supply inside liver tumors and liver metastases that leads to effective tumor control and reduced recurrence of tumors without the use of chemotherapy drugs.
"We are gratified that Dr. Orsi has developed this micro-bland embolization technique and demonstrated that the unique and very precise calibration of Embozene(TM) Microspheres leads to superior clinical findings in the treatment of liver cancer," said Thomas A. Gordy, President and Chief Executive Officer, CeloNova Biosciences. "Embozene(TM) Microspheres, unlike other embolics, are precisely calibrated so that larger spheres do not prevent the deepest possible penetration of tumors. Patients with liver cancer treated in this new way can experience a longer life and a better quality of life."
About CeloNova BioSciences, Inc.
Headquartered in Newnan, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are enhanced by one of the Company's proprietary materials, Polyzene(R)-F, a highly lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The Company's current products include Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Both products are CE marked and Embozene(TM) Color Advanced microspheres have been approved by the US FDA. For more information, please visit www.celonova.com.
AP PhotoExpress Network: PRN9
PRN Photo Desk, firstname.lastname@example.orgCeloNova BioSciences, Inc.